EP3808846A1 — Modified double-stranded rna agents
Assigned to Alnylam Pharmaceuticals Inc · Expires 2021-04-21 · 5y expired
What this patent protects
The present invention relates to a double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene, comprising a sense strand and an antisense strand, with a duplex region of 17-21 nucleotide pairs in length, wherein the dsRNA agent is represented by formu…
USPTO Abstract
The present invention relates to a double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene, comprising a sense strand and an antisense strand, with a duplex region of 17-21 nucleotide pairs in length, wherein the dsRNA agent is represented by formula (I):wherein:B1 is 2'-OMe or 2'-F, n<sup>1</sup> is 8, T1 is 2'F, n<sup>2</sup> is 3, B2 is 2'-OMe, n<sup>3</sup> is 7, n<sup>4</sup> is 0, B3 is 2'-OMe, n<sup>5</sup> is 3, B1' is 2'-OMe or 2'-F, q<sup>1</sup> is 9, Tl' is 2'-F, q<sup>2</sup> is 1, B2' is 2'-OMe or 2'-F, q<sup>3</sup> is 4, q<sup>4</sup> is 0, B3' is 2'-OMe or 2'-F, q<sup>5</sup> is 7, T3' is 2'-F, q<sup>6</sup> is 1, B4' is 2' OMe, and q<sup>7</sup> is 1.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.